Effect of azacitidine (AZA) on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission

被引：41

作者：

List, A. F.

Fenaux, P.

Mufti, G. J.

Hellstroem-Lindberg, E.

Gore, S.

Bennett, J. M.

Silverman, L. R.

Backstrom, J.

Allen, A. R.

Beach, C. L.

机构：

[1] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA

[2] Univ Paris 13, Hop Avicenne, Bobigny, France

[3] Kings Coll Hosp London, London, England

[4] Karolinska Univ Hosp, Stockholm, Sweden

[5] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[6] Univ Rochester, Rochester, NY USA

[7] Mt Sinai Sch Med, New York, NY USA

[8] Pharmion Corp, Overland Pk, KS USA

[9] Pharmion Corp, San Francisco, CA USA

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.7006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7006

引用

页数：1